ACS Central Science · 2022 · 75 citations · 23 references
Life SciencesNeurobiologyNeuroscienceDrug DeliveryNanomaterialsNeurodegenerationNanocarriers For TherapeuticsNanomedicineNanoparticle Delivery SystemsNanoparticle DesignNeurodegenerative DiseasesNeuroprotectionAlpha-synuclein AggregationAlpha-synuclein-targeted TherapyBlood-brain Barrier PermeabilityDopaminergic NeuronsNanocrystalsNanoparticle Delivery VectorsNanoparticle-based ProbesNeuroprotective Mechanisms
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the gradual loss of dopaminergic neurons in the substantia nigra and the accumulation of α-synuclein aggregates called Lewy bodies. Here, nanodecoys were designed from a rabies virus polypeptide with a 29 amino acid (RVG29)-modified red blood cell membrane (RBCm) to encapsulate curcumin nanocrystals (Cur-NCs), which could effectively protect dopaminergic neurons. The RVG29-RBCm/Cur-NCs nanodecoys effectively escaped from reticuloendothelial system (RES) uptake, enabled prolonged blood circulation, and enhanced blood-brain barrier (BBB) crossing after systemic administration. Cur-NCs loaded inside the nanodecoys exhibited the recovery of dopamine levels, inhibition of α-synuclein aggregation, and reversal of mitochondrial dysfunction in PD mice. These findings indicate the promising potential of biomimetic nanodecoys in treating PD and other neurodegenerative diseases.
23
Protocol for the MPTP mouse model of Parkinson's disease
Vernice Jackson‐Lewis, Serge Przedborski · Nature Protocols · 2007 · 1.1K citations
Ligand-Modified Cell Membrane Enables the Targeted Delivery of Drug Nanocrystals to Glioma
Zhilan Chai, Danni Ran, Linwei Lu et al. · ACS Nano · 2019 · 356 citations
Pharmacy, Oncology, Pharmaceutics +17